TRANSFORMING THE WAY WE SEE DISEASE
Elucid Labs™ aims to democratize AI-powered point-of-care medicine by performing digital biopsy. Elucid Labs™ is a MedTech startup building the world's first AI-powered computational imaging device that is capable of detection and diagnosis of various diseases without the need for invasive procedures for the purposes of diagnosis and treatment planning. Currently, Elucid is building the world’s first AI dermatology assistant (AIDA™) system for providing clinical decision support as well as productivity tool to medical practitioners for early detection and non-invasive diagnosis of skin cancer and diseases. AIDA™ fuses our proprietary digital biopsy computational Hypodermoscopy™ imager with an explainable deep learning engine to give clinicians new insights into skin diseases. AIDA's patent pending computational imaging technology probes the molecular makeup of the skin at different layers and produces a 4000-parameter unique fingerprint for the lesion. AIDA's proprietary deep learning technology translates this fingerprint into valuable clinical knowledge to assist physicians in making better, faster, and well-informed decisions regarding diagnosis and course of treatment. Using Elucid Labss in-vivo digital biopsy capability, detection and diagnosis of skin cancer can be performed in a matter of seconds at much earlier stages of development, in turn reducing the cost of treatment as well as significantly reducing the unnecessary medical procedures carried out every year, while improving patient experience and outcome. Elucid Labs™ will enable individuals to proactively participate in preventative personalized healthcare.
Elucid Labs™ aims to democratize AI-powered point-of-care medicine by performing digital biopsy. Elucid Labs™ is a MedTech startup building the world's first AI-powered computational imaging device that is capable of detection and diagnosis of various diseases without the need for invasive procedures for the purposes of diagnosis and treatment planning. Currently, Elucid is building the world’s first AI dermatology assistant (AIDA™) system for providing clinical decision support as well as productivity tool to medical practitioners for early detection and non-invasive diagnosis of skin cancer and diseases. AIDA™ fuses our proprietary digital biopsy computational Hypodermoscopy™ imager with an explainable deep learning engine to give clinicians new insights into skin diseases. AIDA's patent pending computational imaging technology probes the molecular makeup of the skin at different layers and produces a 4000-parameter unique fingerprint for the lesion. AIDA's proprietary deep learning technology translates this fingerprint into valuable clinical knowledge to assist physicians in making better, faster, and well-informed decisions regarding diagnosis and course of treatment. Using Elucid Labss in-vivo digital biopsy capability, detection and diagnosis of skin cancer can be performed in a matter of seconds at much earlier stages of development, in turn reducing the cost of treatment as well as significantly reducing the unnecessary medical procedures carried out every year, while improving patient experience and outcome. Elucid Labs™ will enable individuals to proactively participate in preventative personalized healthcare.
AS FEATURED IN:
|
|
|
|
LATEsT NEWS
Mar 24 2018 - Elucid Labs researcher spoke at Waterloo Innovation Summit
Mar 12 2018 - Elucid Labs featured in Success Stories article by Invest Ontario
Nov 22 2017 - Elucid Labs speaks about Waterloo MedTech conference
Oct 13 2017 - Elucid Labs speaks about AI at Waterloo Meets AI event
Oct 13 2017 - Elucid Labs joins C100 48Hrs in the Valley program
Oct 04 2017 - Elucid Labs featured in Waterloo Chronicle article
Sep 07 2017 - Elucid Labs named by CIX as one of Canada's top 20 most innovative companies
July 18 2017 - Elucid Labs joins Nvidia Inception accelerator program
Jun 15 2017 - Elucid Labs featured in New York Times and Arkansas Gazette
May 19 2017 - Elucid Labs researchers wins AI award
May 16 2017 - Elucid Labs team member featured in Waterloo Magazine
May 01 2017 - Elucid Labs team member featured in Canadian Business
Apr 19 2017 - Elucid Labs receives funding from Spectrum28 fund
Mar 13 2017 - Elucid Labs team member gives lecture on AI at WICI
Jan 29 2016 - Elucid Labs team member spoke about AI at Big Ideas Discussion Panel
Dec 16 2016 - Elucid Labs team members edge out leading institutions to win AI award
Mar 12 2018 - Elucid Labs featured in Success Stories article by Invest Ontario
Nov 22 2017 - Elucid Labs speaks about Waterloo MedTech conference
Oct 13 2017 - Elucid Labs speaks about AI at Waterloo Meets AI event
Oct 13 2017 - Elucid Labs joins C100 48Hrs in the Valley program
Oct 04 2017 - Elucid Labs featured in Waterloo Chronicle article
Sep 07 2017 - Elucid Labs named by CIX as one of Canada's top 20 most innovative companies
July 18 2017 - Elucid Labs joins Nvidia Inception accelerator program
Jun 15 2017 - Elucid Labs featured in New York Times and Arkansas Gazette
May 19 2017 - Elucid Labs researchers wins AI award
May 16 2017 - Elucid Labs team member featured in Waterloo Magazine
May 01 2017 - Elucid Labs team member featured in Canadian Business
Apr 19 2017 - Elucid Labs receives funding from Spectrum28 fund
Mar 13 2017 - Elucid Labs team member gives lecture on AI at WICI
Jan 29 2016 - Elucid Labs team member spoke about AI at Big Ideas Discussion Panel
Dec 16 2016 - Elucid Labs team members edge out leading institutions to win AI award
PUBLICATIONS
J. Arlette, Alexander Wong, Iman Khodadad, Farnoud Kazemzadeh. Deep Tissue Sequencing Using Augmented Intelligence to Probe Melanocytic Lesions. Journal of Cutaneous Medicine and Surgery. 21(6) 572. 2017. [PDF]
CAREER OPPORTUNITIES
Join Elucid Labs™ in one of the following exciting roles:
Contact Us
|
|
|
|
|
Elucid Labs, AIDA, and Hypodermoscopy are trademarks of Elucid Labs Inc.
